Loading...
•
Sep 30, 2020
Repare Therapeutics Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020, and provided recent business highlights.
Key Takeaways
Repare Therapeutics reported financial results for Q3 2020. They have advanced their RP-3500 program and expect to initiate a Phase 1 clinical trial for RP-6306 in Q3 2021, ahead of their previously conveyed timeline.
Advanced CCNE-1 synthetic lethal inhibitor (now designated RP-6306) program into Good Laboratory Practice (GLP) toxicology studies ahead of original timeline.
Initiated a Phase 1/2 clinical trial evaluating RP-3500 as a monotherapy and in combination with Pfizer's PARP inhibitor, talazoparib, in patients with solid tumors.
Inaugurated a newly expanded laboratory and office facility in Montreal, Quebec.
Appointed Dr. Laurence F. Akiyoshi as its Executive Vice-President, Organizational and Leadership Development.